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Olfactory neuroblastoma – a rare tumour under the guise of 
chronic rhinosinusitis
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 Olfactory neuroblastoma (ONB), also called esthesioneuroblastoma, is a rare tumour that occurs in the nasal cavity and 
paranasal sinuses. The symptoms that patients report are similar to chronic rhinosinusitis (CRS). The authors present the 
case of a patient referred to hospital due to nasal obstruction on the left side. The performed endoscopic surgery revealed 
within the left middle nasal concha a tumour penetrating into the anterior ethmoid and frontal recess. ONB was diagnosed 
in the histopathological examination. The patient was qualified for complementary radiotherapy. The patient has been 
under medical supervision for 24 months. There have been no signs of recurrence. It was decided to present the above 
case due to the lack of deviations in the ENT endoscopy and minor ailments reported by the patient, which in combination 
with advanced age could lead to discontinuation of surgical treatment.
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Introduction
Olfactory neuroblastoma (ONB), also called esthesioneurobla-
stoma, is a rare tumour, occurring in 0.4 to 1 case per million 
[1], and accounts for 3–6% of all malignant tumours of the 
nasal cavity and sinuses [2]. The tumour is locally malignant, 
infiltrates the nasal cavity, sinuses, cribriform plate, orbit and 
cranial cavity.
The origin of the tumour is controversial. It is believed 
that the starting point of tumour cells are primary olfactory 
epithelial progenitor cells. The neuronal origin of the tumour or 
the origin from the neural crest cells is demonstrated primarily 
by the presence of neurofilaments [3].
In order to determine the clinical advancement of ONB, the 
Kadish staging system from A to D [4] is most commonly used. 
In situ tumour, restricted to the nasal septum, floor, lateral wall, 
nasal passage, nasal concha or nasal vestibule with/without 
bone infiltration is designated as stage A. A tumour stretching 
beyond paranasal sinuses or extending to the sinuses or an 
ostiomeatal complex is classified as stage B. Infiltration of the 
skull base, palate, cribriform plate, medial wall or orbital wall, 
pterygoid plates, nasopharynx, skin, dura mater and brain is 
qualified as grade C. Patients with the involvement of lymph 
nodes or internal organs are classified as grade D.
The TNM modification proposed by Dulguerov and Cal-
caterrain [5] is also used: T1 – tumour involves the nasal cavity 
and/or sinuses (except the sphenoid sinus), ethmoid cells, T2 
– tumour involves the nasal cavity and/or sinuses along with 
the sphenoid sinus, with infiltration or erosion of the cribriform 
plate, T3 – tumour infiltrates the orbital tissue or spreads to 
the front of the skull base, T4 – tumour spreads to the brain, 
N0 – no cervical lymph node metastases, N1 – any form of 
cervical lymph node metastases, M0 – no metastases, M1 – 
distant metastases. A similar classification is proposed by the 
American Joint Committee on Cancer (AJCC) that separately 
describes the tumour invasion in the TNM scale depending on 
the tumour origin, within the nasal cavity and ethmoid cells, or 
in the maxillary sinus [6]. Unfortunately, Kadish staging systems, 
Dulguerov’s modified TNM, and AJCC TNM, all poorly depict 
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patient prognosis over a 10-year horizon [6]. Histopathological 
evaluation of the tumour is based on the Hyam’s classification 
in stages from I to IV [7].
Clinical symptoms are varied. The most common ones 
include nasal obstruction (90%), preceded by bleeding (30%). 
Anosmia, headaches, facial pain, sinusitis, diplopia, epiphora, 
proptosis with the orbit involvement are less frequent [8, 9]. 
Kuan [10], in a retrospective analysis of data from 40 years, 
found that in 841 patients with ONB the tumour originated 
from the nasal cavity in 83% of cases, followed by the eth-
moid sinus – 3.9%, maxillary sinus – 1.3%, sphenoidal sinus 
– 0.7% and frontal sinus – 0.35%. The presence of lymph node 
metastases was quite rare (less than 10%), most commonly 
these were group II lymph nodes. There was no relationship 
between the presence of lymph nodes metastases and the 
primary location of the tumour. No recommendation can be 
made about the elective neck dissection or radiation therapy 
of the N0 neck [11].
High-resolution magnetic resonance imaging, thin-cut 
maxillofacial computed tomography (CT), and fluorodeoxy-
glucose positron emission tomography combined with CT 
were performed preoperatively in each case. 
Case report
In August 2017, a 74-year-old patient was admitted to the 
Department of Laryngology and Laryngological Oncology 
due to nasal obstruction on the left side. The patient did not 
report any pain, nasal bleeding or recurrent inflammation. 
Tomographic examination of the sinuses revealed abnormal 
soft-tissue masses with the presence of calcification in the left 
middle nasal concha penetrating into the anterior ethmoid, 
frontal recess and nasolacrimal canal. The left frontal sinus 
was airless. The size of the lesion was 29 x 20 x 24 mm (Fig. 1 
and 2). The patient suffered from hypertension, varicose veins 
and ulceration of the lower limbs. Endoscopic examination 
revealed a distended, enlarged middle nasal concha. Based 
on the tomographic examination, the extent of the lesion was 
estimated at 6 points on the Lund-MacKay scale.
No enlarged lymph nodes were found in the palpation and 
radiological examination. Endoscopic sinus surgery (ESS) was 
performed under general anesthesia with hypotension. The 
distended, enlarged left middle nasal concha was incised and 
granular tissue masses suggesting inverted papilloma were 
collected. The lateral lamella of the concha, uncinate process 
were removed, the maxillary sinus ostium was widened. The 
sinus cavity was clean. Then the anterior ethmoid and frontal 
recess were opened. The left frontal sinus was filled with mucus 
content. There were no deviations from the normal state on 
the right side of the nasal cavity. Material for histopathological 
and bacteriological examination was collected. 
Histopathological examination revealed olfactory es-
thesioneuroblastoma, Hyam’s grade II EMA(–), CK(–), VIM(–), 
LCA(–), ABpaS(–), Ki <5%, NSE(+), SNPF(+), S100(–), ChromA(+). 
The lesion in the Kadish scale was grade B (despite originating 
from the middle concha, it spread to the frontal recess), in the 
TNM scale – T1N0M0 scale. Escherischia coli, Staphylococcus 
hominis were cultured. After the oncological consultation, 
a decision was taken to extend the procedure. ESS was perfor-
med, removing the remainder of the middle concha, opening 
widely the ethmoid and frontal recess, removing the orbital 
lobe and clearing the ethmoid roof. Margins were collected 
stating tumour infiltration in the rest of the middle concha and 
frontal recess. The patient was qualified for complementary 
radiotherapy.
The patient is examined endoscopically every 3 months 
and radiologically every 6 months. Up to now, 24 months after 
surgery, there have been no recurrent tumour features (Fig. 3).Figure 1. CT scan before the surgery
Figure 2. The size of the lesion in CT scan
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Discussion
The generally accepted method of ONB treatment is surgery 
with subsequent radiotherapy. Surgical techniques include 
transnasal craniofacial resection with/without craniotomy 
or expanded endoscopic endonasal craniofacial resection, 
depending on the tumour location and extension [5, 11]. 
The development of endoscopic techniques allows for safe 
resection of advanced tumours, and preservation of olfactory 
function may be considered for patients with ONBs showing 
no invasion in the contralateral side [9, 12]. Adjuvant che-
motherapy is sometimes added for high-grade, recurrent, or 
locoregionally advanced tumours [11, 13]. The comparison 
of surgical treatment, chemotherapy and radiotherapy, as 
the only therapy combined with surgical methods, showed 
that better results were obtained in the case of surgery and 
subsequent radiotherapy [1, 14].
It has been found that a bad prognostic factor is the high 
grade in Hyam’s scale and the presence of lymph nodes meta-
stases. Examining the results of the 5-year and 10-year survival, 
it was observed that patients in stage A lived shorter than in 
stage B, regardless of whether they were treated only surgically 
or in combination with subsequent radiotherapy.
Perhaps this is the result of a more radical surgical treat-
ment of B-stage tumours [2]. A retrospective analysis of 876 
patients showed that an important prognostic factor for ONB 
recurrence was age >60 years [15]. Patients require regular 
oncological and laryngological follow-ups. Magnetic resonan-
ce imaging after surgery is suggested every 3 months in the 
first year after surgery, regardless of the regular endoscopic 
examination of the nasal cavity.
The described case suggests the importance of perfor-
ming accurate endoscopic examination of the nasal cavity 
in combination with computed tomography in patients over 
60, reporting even minor disturbances, especially one-sided. 
Early surgical intervention gives the patients a chance to be 
treated definitively. 
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Figure 3. MR scan 24 months after surgery
